静脉阿米舒必利预防术后恶心呕吐的两项随机对照试验
两项设计基本相同的随机双盲安慰剂对照III期研究,评估静脉阿米舒必利5 mg在成人全麻手术患者中预防术后恶心呕吐的疗效。美国研究显示阿米舒必利组完全缓解率46.9%优于安慰剂组33.8%(P=0.026),欧洲研究为57.4%对46.6%(P=0.070),安全性无临床显著差异。
要点
- 静脉阿米舒必利5 mg可降低中高危术后恶心呕吐风险
- 美国研究达主要终点,欧洲研究未达统计学显著
- 安全性良好,QT延长、锥体外系反应和镇静无差异
核心结论
- 一项试验显示优效性,事后合并分析支持阿米舒必利安全且优于安慰剂减少术后恶心呕吐。
研究设计与样本
- 两项基本相同的随机双盲安慰剂对照平行组III期研究,在美国9个和欧洲10个中心进行。
- 纳入全麻下择期手术且至少有两个Apfel危险因素的成人住院患者,共随机给药689例,符合方案可评估626例。
- 诱导时单次给予阿米舒必利5 mg或匹配安慰剂。
主要发现
- 美国研究完全缓解率阿米舒必利组46.9%(95%CI 39.0-54.9),安慰剂组33.8%(95%CI 26.2-42.0),P=0.026。
- 欧洲研究完全缓解率阿米舒必利组57.4%(95%CI 49.2-65.3),安慰剂组46.6%(95%CI 38.8-54.6),P=0.070。
- 阿米舒必利组恶心发生率低于安慰剂组。
- 安全性特征无临床显著差异,QT延长、锥体外系副作用或镇静方面无差异。
关键数值与推荐
- 主要终点为术后24小时内无呕吐/干呕且未使用止吐救援药物(完全缓解)。
- 恶心发生率为次要终点。
临床怎么用
- 对于中高危术后恶心呕吐的成人全麻手术患者,可考虑诱导时单次静脉给予阿米舒必利5 mg以预防术后恶心呕吐。
局限性
- 两项研究结果不完全一致,欧洲研究未达统计学显著性。
- 事后合并分析为分析计划变更,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two essentially identical, randomized, double-blind, placebo-controlled, parallel-group phase III studies evaluated the efficacy of intravenous amisulpride, a dopamine D2/D3 antagonist, in the prevention of postoperative nausea and vomiting in adult surgical patients. METHODS: Adult inpatients undergoing elective surgery during general anesthesia and having at least two of the four Apfel risk factors for postoperative nausea and vomiting were enrolled at 9 U.S. and 10 European sites. A single 5-mg dose of amisulpride or matching placebo was given at induction of anesthesia. The primary endpoint was complete response, defined as no vomiting/retching and no use of antiemetic rescue medication in the 24-h postoperative period. Nausea incidence was a secondary endpoint. RESULTS: Across the two studies, 689 patients were randomized and dosed with study medication, of whom 626 were evaluable per protocol. In the U.S. study, 46.9% (95% CI, 39.0 to 54.9) of patients achieved complete response in the amisulpride group compared to 33.8% (95% CI, 26.2 to 42.0) in the placebo group (P = 0.026). In the European study, complete response rates were 57.4% (95% CI, 49.2 to 65.3) for amisulpride and 46.6% (95% CI, 38.8 to 54.6) for placebo (P = 0.070). Nausea occurred less often in patients who received amisulpride than those who received placebo. There was no clinically significant difference in the safety profile of amisulpride and placebo; in particular, there were no differences in terms of QT prolongation, extrapyramidal side effects, or sedation. CONCLUSIONS: One of the two trials demonstrated superiority, while pooling both in a post hoc change to the plan of analysis supported the hypothesis that amisulpride was safe and superior to placebo in reducing the incidence of postoperative nausea and vomiting in a population of adult inpatients at moderate to high risk of postoperative nausea and vomiting.
引用
- Gan TJ, Kranke P, Minkowitz HS, et al. Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials. Anesthesiology. 2017. PMID: 27902493. doi:10.1097/ALN.0000000000001458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。